Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Artur Jurczyszyn, Julio Davila, K. Martin Kortüm, David S. Jayabalan, Ravi Vij, Mark Fiala, Vibor Milunovic, C. S. Chim, Katarzyna Wiśniewska-Piąty, Anna Waszczuk-Gajda, Edvan Crusoe, Roman Hajek, Paweł Robak, Małgorzata Raźny, Daria Zawirska, Max Bittrich, Hareth Nahi, Jieqi Liu, Jorge J. Castillo, David H. Vesole

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalLeukemia and Lymphoma
Issue number2
StatePublished - Jan 28 2019


  • Early-onset multiple myeloma
  • prognosis
  • survival
  • treatment response


Dive into the research topics of 'Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases'. Together they form a unique fingerprint.

Cite this